The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite ...

Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

Momentum is building for PROTAC treatments that eliminate disease-causing proteins, including those responsible for difficult ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

There is currently no FDA-approved targeted amino acid PET agent for brain cancer imaging available in the US. TLX101-CDx was previously granted Orphan Drug and Fast Track designations by the FDA.

Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...